Andrew Vickers

Andrew Julian Vickers
Born (1967-02-11) 11 February 1967
Alma mater University of Cambridge, University of Oxford
Scientific career
Fields Oncology, biostatistics
Institutions Memorial Sloan Kettering Cancer Center
Thesis Homeopathy and clinical trials (1999)

Andrew Julian Vickers (born 11 February 1967)[1][2] is a biostatistician and attending research methodologist at Memorial Sloan Kettering Cancer Center. Since 2013, he has also been professor of public health at Weill Cornell Medical College.[3] He is the statistical editor for the peer-reviewed journal European Urology.[4]

Education and career

Vickers received his B.A. from the University of Cambridge in 1989 and his D.Phil. from the University of Oxford in 1999.[5] He joined Memorial Sloan Kettering in 1999 as an assistant attending research methodologist, before being appointed an associate attending research methodologist there in 2006 and an attending research methodologist in 2012.[5]

Research

He is known for his research into prostate cancer screening,[6] statistical methodology for the evaluation of prediction models[7] and clinical trial methodology.[8] He is part of the team that developed the 4Kscore,[9] a test that accurately identifies a man's risk of aggressive prostate cancer. In 2011, Vickers published a study which found that PSA velocity—the change in the blood level of prostate-specific antigen (PSA)--was not a more accurate predictor of prostate cancer than comparing PSA levels to a specific threshold.[10] Vickers was the lead author of a 2012 meta-analysis of 29 acupuncture trials published in the Archives of Internal Medicine.[11] Vickers leads the "Amplio" quality assurance initiative at Memorial Sloan Kettering[12] and is Director of the "Web Survey" health informatics core facility.[13]

Personal life

Vickers is also a competitive runner.[14] He has a daughter and two sons.[15][16]

References

  1. "Reference Entry". Who's Who. Oxford University Press. Retrieved 1 August 2015.
  2. "Andrew Vickers". Library of Congress Name Authority File. Retrieved 23 April 2017.
  3. "News and Highlights". Weill Cornell Medical College. July 2013. Retrieved 6 June 2015.
  4. "Andrew Vickers". European Urology website. Retrieved 6 March 2018.
  5. 1 2 "Andrew J. Vickers CV" (PDF). Retrieved 5 June 2015.
  6. "Rise in PSA protein 'not prostate cancer sign'". BBC News. 25 February 2011. Retrieved 5 June 2015.
  7. Vickers, Andrew; Elkin, Elena (2006). "Decision curve analysis: a novel method for evaluating prediction models". Medical Decision Making. 26: 565–74. doi:10.1177/0272989X06295361. PMC 2577036. PMID 17099194.
  8. Vickers, Andrew (2014). "Clinical trials in crisis: Four simple methodologic fixes". Clinical Trials. 11: 615–21. doi:10.1177/1740774514553681. PMC 4229450.
  9. "4Kscore Patient Site".
  10. Vickers, A. J.; Till, C.; Tangen, C. M.; Lilja, H.; Thompson, I. M. (24 February 2011). "An Empirical Evaluation of Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer Detection". JNCI Journal of the National Cancer Institute. 103 (6): 462–469. doi:10.1093/jnci/djr028. PMC 3057983.
  11. Vickers, AJ; Cronin, AM; Maschino, AC; Lewith, G; MacPherson, H; Foster, NE; Sherman, KJ; Witt, CM; Linde, K; Acupuncture Trialists', Collaboration (22 October 2012). "Acupuncture for chronic pain: individual patient data meta-analysis". Archives of Internal Medicine. 172 (19): 1444–53. doi:10.1001/archinternmed.2012.3654. PMC 3658605. PMID 22965186.
  12. "Should Surgeons Keep Score? – Backchannel". Medium. Retrieved 10 December 2015.
  13. "Andrew Vickers". Memorial Sloan Kettering Cancer Center. Retrieved 7 March 2018.
  14. Aschwanden, Christie (30 October 2014). "Introducing Slate's Marathon Time Predictor". Slate. Retrieved 25 August 2015.
  15. Henning, Justine (2017-04-21). ""Science is why my cancer diagnosis isn't a death sentence. Today I march for science."". Vox. Retrieved 7 March 2018.
  16. Somers, James (2014-12-12). "Should Surgeons Keep Score?". WIRED. Retrieved 7 March 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.